Insider Selling: Ophthotech Corp (NASDAQ:OPHT) Insider Sells 3,798 Shares of Stock

Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 3,798 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $3.17, for a total value of $12,039.66. Following the sale, the insider now owns 42,458 shares in the company, valued at $134,591.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ophthotech Corp (OPHT) traded up $0.06 on Friday, reaching $2.85. The company’s stock had a trading volume of 229,639 shares, compared to its average volume of 476,232. The company has a market capitalization of $100.55, a P/E ratio of 1.82 and a beta of 1.58. Ophthotech Corp has a twelve month low of $2.24 and a twelve month high of $5.05.

Institutional investors and hedge funds have recently bought and sold shares of the business. Federated Investors Inc. PA raised its holdings in Ophthotech by 102.3% in the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 28,040 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Ophthotech by 73.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 49,928 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Ophthotech by 3.2% during the first quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 7,501 shares in the last quarter. First Manhattan Co. bought a new position in shares of Ophthotech during the third quarter valued at $1,201,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Ophthotech by 28.1% during the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after acquiring an additional 143,349 shares in the last quarter. Institutional investors and hedge funds own 62.48% of the company’s stock.

OPHT has been the subject of several research reports. Zacks Investment Research raised Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 target price for the company in a research note on Monday, November 13th. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price objective on shares of Ophthotech in a research note on Thursday, September 21st. TheStreet raised Ophthotech from an “e+” rating to a “c” rating in a research note on Thursday, November 30th. Finally, ValuEngine upgraded Ophthotech from a “hold” rating to a “buy” rating in a report on Monday, October 2nd.

WARNING: “Insider Selling: Ophthotech Corp (NASDAQ:OPHT) Insider Sells 3,798 Shares of Stock” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/ophthotech-corp-opht-insider-david-r-guyer-sells-3798-shares.html.

About Ophthotech

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply